US FDA approves KamadaKamada’s application to manufacture Cytogam

2023-05-04
Pharmaceutical Technology
上市批准免疫疗法
US FDA approves Kamada’s application to manufacture Cytogam
Preview
来源: Pharmaceutical Technology
Cytogam is indicated for prophylaxis of cytomegalovirus disease associated with pancreas, lung, heart, liver and kidney transplantation. Credit:. Volkova via Shutterstock.com.
The US Food and Drug Administration (FDA) approved Kamada’s application to manufacture Cytogam (cytomegalovirus immune globulin intravenous [human]) at its facility located in Beit Kama, Israel.
The regulatory approval represents the completion of the Cytogam technology transfer process from CSL Behring, its previous manufacturer.
Recommended Reports
US FDA approves Kamada’s application to manufacture Cytogam
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Ropidoxuridine in Sarcomas GlobalData
US FDA approves Kamada’s application to manufacture Cytogam
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - AVCN-583601 in Epidermolysis Bullosa GlobalData
View all
Kamada stated that the technology transfer supplement includes the manufacture of an upstream protein solution undertaken by Prothya Biosolutions at its facility in Belgium.
Acquired from Saol Therapeutics, Cytogam is indicated for the prophylaxis of cytomegalovirus disease associated with pancreas, lung, heart, liver and kidney transplantations.
It is claimed to be the only immunoglobulin (IgG) product to receive FDA approval for this indication.
In 2022, the therapy generated $23m in sales.
Kamada CEO Amir London stated: “The US FDA approval of this application to manufacture Cytogam, which was granted within our expected timeline following a successful on-site inspection by the FDA, represents a significant accomplishment for KamadaKamada.
“This is the third product, in addition to Glassia and Kedrab, to be approved by the FDA for manufacturing at our Israeli site.
“We intend to initiate commercial manufacturing of Cytogam at our Israeli facility shortly, which will positively impact the facility’s utilisation and efficiency.”
In January 2023, the company submitted a similar technology transfer application to the Canadian health authorities, where it is now under review.
In 2020, Kamada collaborated with Kedrion Biopharma in the development, manufacture and distribution of a human plasma-derived polyclonal IgG product to treat Covid-19.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。